JHS Svendgaard Laboratories Ltd
NSE: JHS BSE: 532771
₹8.86
(-1.12%)
Fri, 15 May 2026, 08:08 pm
Market Cap749.89M
PE Ratio0
Dividend0
Consumer Non-Durables
Household/Personal Care
24.5KJHS Svendgaard Laboratories Analysis
dividend
- Unable to calculate sustainability of dividends as JHS Svendgaard Laboratories has not reported any payouts.
- Unable to evaluate JHS Svendgaard Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate JHS Svendgaard Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- JHS Svendgaard Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Debt is covered by short term assets, assets are 17.5x debt.
- JHS Svendgaard Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (124.4% vs 3.2% today).
- JHS Svendgaard Laboratories's level of debt (3.2%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- High level of physical assets or inventory.
management
- The tenure for the JHS Svendgaard Laboratories board of directors is about average.
- Paramvir's remuneration is lower than average for companies of similar size in India.
- The average tenure for the JHS Svendgaard Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
- Paramvir's compensation has increased whilst company is loss making.
misc
- JHS Svendgaard Laboratories is not covered by any analysts.
- JHS Svendgaard Laboratories has significant price volatility in the past 3 months.
past
- Unable to compare JHS Svendgaard Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
- JHS Svendgaard Laboratories does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- JHS Svendgaard Laboratories used its assets less efficiently than the IN Personal Products industry average last year based on Return on Assets.
- It is difficult to establish if JHS Svendgaard Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if JHS Svendgaard Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare JHS Svendgaard Laboratories's 1-year growth to the IN Personal Products industry average as it is not currently profitable.
value
- JHS Svendgaard Laboratories is good value based on assets compared to the IN Personal Products industry average.
- BSE:532771 is up 38.6% outperforming the Personal Products industry which returned 3.7% over the past month.
- BSE:532771 is up 38.6% outperforming the market in India which returned 8% over the past month.
- JHS Svendgaard Laboratories is loss making, we can't compare its value to the IN Personal Products industry average.
- JHS Svendgaard Laboratories is loss making, we can't compare the value of its earnings to the India market.
- 532771 underperformed the Personal Products industry which returned -5.3% over the past year.
- 532771 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800